Další formáty:
BibTeX
LaTeX
RIS
@article{1341575, author = {Kotašková, Jana and Pavlová, Šárka and Greif, Igor and Stehlíková, Olga and Plevová, Karla and Janovská, Pavlína and Brychtová, Yvona and Doubek, Michael and Pospíšilová, Šárka and Bryja, Vítězslav}, article_location = {Hoboken}, article_number = {2}, doi = {http://dx.doi.org/10.1111/bjh.13848}, keywords = {ROR1; cell isolation; chronic lymphocytic leukaemia; complete remission}, language = {eng}, issn = {0007-1048}, journal = {British Journal of Haematology}, title = {ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells}, url = {http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf}, volume = {175}, year = {2016} }
TY - JOUR ID - 1341575 AU - Kotašková, Jana - Pavlová, Šárka - Greif, Igor - Stehlíková, Olga - Plevová, Karla - Janovská, Pavlína - Brychtová, Yvona - Doubek, Michael - Pospíšilová, Šárka - Bryja, Vítězslav PY - 2016 TI - ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells JF - British Journal of Haematology VL - 175 IS - 2 SP - 339-342 EP - 339-342 PB - Wiley-Blackwell SN - 00071048 KW - ROR1 KW - cell isolation KW - chronic lymphocytic leukaemia KW - complete remission UR - http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf L2 - http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf N2 - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in the Western world. This lymphoproliferative disorder is defined by the presence of at least 5 9 106 clonal lymphocytes/ml peripheral blood (Hallek,2015). The biggest clinical challenge is the fact that CLL eradication by any available therapy, apart from allogeneic stem cell transplantation, fails to cure the disease, inducing only temporary disease remission, i.e., when the disease does not manifest clinically but CLL cells still persist in the body. During this phase a population of CLL cells often slowly re-expands to trigger CLL relapse. The relapse is often based on the poorly understood but clinically important process of therapy-driven selection of more aggressive CLL subclones (Malcikova et al, 2015). ER -
KOTAŠKOVÁ, Jana, Šárka PAVLOVÁ, Igor GREIF, Olga STEHLÍKOVÁ, Karla PLEVOVÁ, Pavlína JANOVSKÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Šárka POSPÍŠILOVÁ a Vítězslav BRYJA. ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. \textit{British Journal of Haematology}. Hoboken: Wiley-Blackwell, roč.~175, č.~2, s.~339-342. ISSN~0007-1048. doi:10.1111/bjh.13848. 2016.
|